Preparing for the Future: Expanding Capacity and Facilitating Multi-modalities

Published on: 
BioPharm International, BioPharm International, Partnerships for Outsourcing May 2022, Volume 2022 eBook, Issue 2
Pages: 24–27

CDMOs need to consistently demonstrate agility as demand increases for newly developed therapeutic modalities.

The COVID-19 pandemic highlighted the potential of an array of modalities within the biopharmaceutical industry. In particular, the success of messenger RNA (mRNA)-based COVID-19 vaccines has encouraged biopharmaceutical companies to explore and utilize these technologies for other diseases and look to rapidly expand their capacity and capabilities in response to an upsurge in demand.

At the end of 2019, the combined market capitalization of the five publicly listed companies focusing on mRNA platforms was $15 billion, and as of August 2021, that value of capitalization reached more than $300 billion (1). This significant boost in market valuation reflects the optimism that mRNA technology can deliver much more and go beyond the current prophylactic COVID-19 vaccines.


Read this article in BioPharm International's Partnerships for Outsourcing eBook.

About the author

James Park is executive vice-president and managing director of the Global Sales Center at Samsung Biologics.

Article details

BioPharm International
eBook: Partnerships for Outsourcing
May 2022
Pages: 24–27


When referring to this article, please cite it as J. Park, “Preparing for the Future: Expanding Capacity and Facilitating Multi-modalities,” BioPharm International Partnerships for Outsourcing eBook (May 2022).